2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lung Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Interventions
Docetaxel
292
Prednisone
241
enzalutamide
195
Leuprolide
185
Radiotherapy
179
Abiraterone Acetate
170
Magnetic Resonance Spectroscopy
163
bicalutamide
141
Goserelin
138
Androgen Antagonists
121
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
108
Radiosurgery
108
apalutamide
93
abiraterone
83
gallium 68 PSMA-11
81
Specimen Handling
73
darolutamide
67
Surveys and Questionnaires
64
Gonadotropin-Releasing Hormone
63
Triptorelin Pamoate
58
Radiation
57
Biopsy
57
Brachytherapy
54
cabazitaxel
53
Standard of Care
51
Radiotherapy, Intensity-Modulated
51
Zoledronic Acid
50
pembrolizumab
49
luprolide acetate gel depot
49
Flutamide
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Histamine Antagonists
×
Clear all
NCT03050866
2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2
Unknown
140 enrolled